advanced

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Spira A, Cho BC, Felip E, Garon EB, Goto K, Johnson M, Leighl N, Passaro A, Planchard D, Popat S, Yang JC, Lu X, Jiang[...]

By sjmartinez • January 8, 2025

Combination immunotherapy for hepatocellular carcinoma

Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023 Mar 16:S0168-8278(23)00178-2. doi: 10.1016/j.jhep.2023.03.003. Epub ahead of print. PMID: 36933770.

By sjmartinez • March 19, 2023